Bovine antibodies targeting primary and recurrent Clostridium difficile disease are a potent antibiotic alternative
Melanie L Hutton, Bliss A Cunningham, Kate E Mackin, Shelley A Lyon, Meagan L James, Julian I Rood, Dena Lyras
Scientific Reports | NATURE PUBLISHING GROUP | Published : 2017
The increased incidence of antibiotic resistant 'superbugs' has amplified the use of broad spectrum antibiotics worldwide. An unintended consequence of antimicrobial treatment is disruption of the gastrointestinal microbiota, resulting in susceptibility to opportunistic pathogens, such as Clostridium difficile. Paradoxically, treatment of C. difficile infections (CDI) also involves antibiotic use, leaving patients susceptible to re-infection. This serious health threat has led to an urgent call for the development of new therapeutics to reduce or replace the use of antibiotics to treat bacterial infections. To address this need, we have developed colostrum-derived antibodies for the preventi..View full abstract
Awarded by Australian Research Council
Awarded by Research Connections
The authors acknowledge the facilities, scientific and technical assistance of the Monash Histology Platform, Department of Anatomy and Developmental Biology, Clayton, Monash University and the Monash Protein Production Unit, Clayton, Monash University for the expression and purification of recombinant Toxin B protein. This work was supported by the Australian Research Council (Linkage project LP110200752) and Research Connections (Grants CF14/3721 and RC47582).